- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
P3 data: Leronlimab phase 3 (Twitter) - Jul 2, 2021
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Journal: Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission. (Pubmed Central) - Jun 23, 2021 After Leronlimab washout, protected macaques remain aviremic, and adoptive transfer of hematologic cells into naïve macaques does not transmit viral infection. These data identify CCR5 blockade with Leronlimab as a promising approach to HIV prophylaxis and support initiation of clinical trials.
- |||||||||| Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Review, Journal: Advances of CCR5 antagonists: From small molecules to macromolecules. (Pubmed Central) - May 27, 2021 This review focus on the recent research processes and pharmacological effects of CCR5 antagonists such as Maraviroc, TAK-779 and PRO 140. After focusing on the therapeutic effect of CCR5 antagonists on AIDS, it also discusses the therapeutic prospect of CCR5 in other diseases such as inflammation and tumor.
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Leronlimab ** (Twitter) - May 12, 2021
- |||||||||| Review, Journal: Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. (Pubmed Central) - Apr 30, 2021
Major classes of membrane-associated protein targets include G protein-coupled receptors (GPCRs) and ion channels that are linked to a wide range of disease indications across all therapeutic areas. This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection.
|